|
|
|
|
||
Strong Buy
Re: BERNSTEIN * Celgene: Natco's Case Getting Weaker; We See Settlement in Q1'15 Barring Revlimid Generic Entry Until 2025/26. Expect concession to be quite modest. Pressure will mount on Natco...Got unrestricted version of July 22nd report - a MUST REA outstanding. painful though that our system enables these unclean hands patent trolls... |
return to message board, top of board |